论文部分内容阅读
目的:探讨新喹诺酮(加替沙星)治疗社区获得性肺炎(CAP)的疗效及不良反应。方法:选择我院2015年1月至2015年12月收治的社区获得性肺炎80例,按照随机原则将全部患者分成对照组和实验组各40例,对照组患者给予头孢呋辛治疗。结果:实验组患者的临床治疗总有效率显著高于对照组患者(P<0.05);在不良反应发生率方面,两组患者比较差异无统计学意义(P>0.05)。结论:新喹诺酮(加替沙星)治疗社区获得性肺炎具有比较显著的临床效果,安全可靠,值得临床推广和应用。
Objective: To investigate the efficacy and side effects of new quinolone (Gatifloxacin) in the treatment of community-acquired pneumonia (CAP). Methods: Eighty patients with community-acquired pneumonia admitted in our hospital from January 2015 to December 2015 were selected. According to the randomized principle, all patients were divided into control group and experimental group, 40 cases each. Patients in the control group were treated with cefuroxime. Results: The total effective rate of clinical treatment in experimental group was significantly higher than that in control group (P <0.05). There was no significant difference between the two groups in the incidence of adverse reactions (P> 0.05). Conclusion: The new quinolone (gatifloxacin) in the treatment of community-acquired pneumonia has a more significant clinical effect, safe and reliable, worthy of clinical promotion and application.